Science News
from research organizations

Potential New Drug Target For Diabetes And Alzheimer's Disease

Date:
July 23, 2009
Source:
Albert Einstein College of Medicine
Summary:
A cellular protein that may prevent nerve cells from dying also helps to improve insulin action and lower blood glucose levels, according to a new study.
Share:
         
Total shares:  
FULL STORY

A single dose of Humanin near-normalizes diabetic levels of glucose in a rat model for type 2 diabetes mellitus.
Credit: Albert Einstein College of Medicine

A cellular protein that may prevent nerve cells from dying also helps to improve insulin action and lower blood glucose levels, according to a study by researchers at Albert Einstein College of Medicine of Yeshiva University  in collaboration with scientists at University of California, Los Angeles (UCLA).

The study, which focuses on diabetic rodents, appears this month in PLoS One and is the first to show a role in glucose metabolism for humanin, a small protein (peptide). The researchers also demonstrated that humanin resembles the peptide leptin by acting on the brain to influence glucose metabolism.

Humanin is found in mitochondria — structures that populate the cytoplasm of cells and provide them with energy. The peptide was first detected in brain nerve cells in 2001, and subsequent studies suggest that it protects nerve cells from death associated with Alzheimer's and other brain disease.

"This new role of humanin in glucose metabolism, in addition to its role in Alzheimer's disease, is very intriguing since scientists have long proposed a link between type 2 diabetes and Alzheimer's disease," says Nir Barzilai, M.D., a co-senior author of the study, the Ingeborg and Ira Leon Rennert Professor of Aging Research, and director of the Institute for Aging Research at Einstein. "Humanin could turn out to be a therapeutic option for two common debilitating diseases that affect millions of people. Additionally, humanin may help treat other age-related diseases."

In the study, Dr. Barzilai and his colleagues infused humanin into the brains of diabetic rats to determine the peptide's effect on glucose metabolism. The infused humanin significantly improved overall insulin sensitivity, both in the liver and in skeletal muscle. Furthermore, a single treatment with a highly-potent form of humanin significantly lowered blood-sugar levels in diabetic rats.

"The improvement in insulin sensitivity caused by centrally administered humanin may be one of the main mechanisms through which humanin regulates cell survival," says Dr. Barzilai. "This may provide another potential mechanism by which humanin protects against Alzheimer's disease."

Humanin's possible link to two age-related diseases — Alzheimer's disease and type 2 diabetes — prompted the researchers to investigate whether age-associated changes in humanin levels occur in rodents and in humans. They found that humanin levels in two brain structures (the hypothalamus and the cortex) and in skeletal muscle decreased with age in rodents, and that circulating blood levels of the peptide decreased with age in people.

"From these results, we conclude that the decline in humanin with age could help explain why Alzheimer's disease and type 2 diabetes are more common in older people," says Dr. Barzilai.

Furthermore, "the remarkable activity of this novel peptide proposes a new role for an emerging class of endogenous molecules derived from the mitochondria that have previously been overlooked and can potentially represent a different paradigm for drug development for a variety of diseases," says Dr. Pinchas Cohen, co-senior author, professor and chief of endocrinology at the Mattel Children's Hospital UCLA  and co-director of the UCSD/UCLA Diabetes/Endocrinology Research Center at the David Geffen School of Medicine at UCLA.

The researchers are currently studying the pharmacokinetics and safety profile of humanin and its analogues.

The paper, is published in the July 22, 2009 issue of PLoS One.

The lead author is Radhika H. Muzumdar, M.D., M.B., assistant professor of pediatrics and of medicine at Einstein. The co-senior authors are Drs. Barzilai and Cohen, with Dr. Barzilai serving as corresponding author. Co-authors include Gil Atzmon, Tamuri Budagov, Linguang Cui, Francine Einstein, Sigal Fishman, and Derek Huffman, Einstein; Aruna Poduval, Children's Hospital Montefiore; Christoph Buettner, Mount Sinai School of Medicine; and Laura Cobb and David Hwang, UCLA.

Funding and Financial Disclosure: This work was supported by grants from the National Institutes of Health. No pharmaceutical or commercial support contributed to this manuscript. There are no conflicts of interests for any of the investigators.

Mattel Children's Hospital UCLA is one of the highest-rated children's hospitals in California, is a vital component of Ronald Reagan UCLA Medical Center, ranked by U.S. News & World Report as the No. 3 hospital in nation and best in the Western United States. Mattel Children's Hospital offers a full spectrum of primary and specialized medical care for infants, children and adolescents. The hospital's mission is to provide state-of-the-art treatment for children in a compassionate atmosphere and to improve the understanding and treatment of pediatric diseases.


Story Source:

The above story is based on materials provided by Albert Einstein College of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Albert Einstein College of Medicine. "Potential New Drug Target For Diabetes And Alzheimer's Disease." ScienceDaily. ScienceDaily, 23 July 2009. <www.sciencedaily.com/releases/2009/07/090721214620.htm>.
Albert Einstein College of Medicine. (2009, July 23). Potential New Drug Target For Diabetes And Alzheimer's Disease. ScienceDaily. Retrieved April 26, 2015 from www.sciencedaily.com/releases/2009/07/090721214620.htm
Albert Einstein College of Medicine. "Potential New Drug Target For Diabetes And Alzheimer's Disease." ScienceDaily. www.sciencedaily.com/releases/2009/07/090721214620.htm (accessed April 26, 2015).

Share This Page:


Health & Medicine News
April 26, 2015

Latest Headlines
updated 12:56 pm ET